In a Phase II clinical trial published in The Lancet in 2008, participants taking tesofensine lost an average of 12.8 kg (28 lbs) over 24 weeks — more than double the weight loss achieved by any obesity drug approved at the time. The compound had originally been investigated for Parkinson’s and Alzheimer’s disease, where researchers noticed something unexpected: every patient in the trials was losing significant weight. That observation pivoted the entire research direction, and tesofensine became one of the most discussed weight-loss compounds of the last two decades.
What Is Tesofensine?
Tesofensine is a triple monoamine reuptake inhibitor (TMRI) — it blocks the reuptake of three neurotransmitters simultaneously: serotonin, dopamine, and norepinephrine. By keeping these neurotransmitters active in synaptic spaces for longer, tesofensine produces two primary effects relevant to weight regulation: significant appetite suppression and a modest but measurable increase in resting metabolic rate.
The compound was originally developed by NeuroSearch, a Danish pharmaceutical company, as a treatment for neurodegenerative conditions. During those neurological trials, the consistent and dramatic weight loss observed in study participants prompted a pivot toward obesity as the primary development focus. The 500mcg formulation reflects the dose range studied in the most pivotal Phase II trial — the dose that produced the highest weight loss results while being evaluated for tolerability.
Research Overview
The landmark tesofensine trial (Astrup et al., The Lancet, 2008) randomized 203 obese patients to receive 0.25mg, 0.5mg, or 1mg of tesofensine daily, or placebo, for 24 weeks. The 0.5mg group lost an average of 11.3 kg (24.8 lbs); the 1mg group lost 12.8 kg (28.2 lbs). By comparison, orlistat — the leading FDA-approved weight-loss drug of the era — produced roughly 5 kg of loss over comparable timeframes. These results represented a step-change improvement over existing pharmacological options.
Beyond the primary weight loss outcome, tesofensine-treated subjects showed improvements in waist circumference, blood pressure, and lipid profiles. The mechanisms proposed include both central appetite suppression (via dopaminergic and serotonergic pathways) and peripheral effects on energy expenditure. Subsequent research has explored tesofensine in combination with metoprolol for cardiovascular management, and in combination with GLP-1 agonists for enhanced metabolic protocols.
Relevant literature: PubMed: Tesofensine obesity research | Google Scholar: Tesofensine clinical trials
Community Discussion
Tesofensine has an active community of researchers and biohackers who have followed its development since the Lancet paper. Discussions typically focus on dose optimization, combination protocols with GLP-1 agonists, cardiovascular monitoring strategies, and practical comparisons with approved weight-loss medications. Starting points: r/Peptides — Tesofensine threads | r/PEDs — Tesofensine discussion.
Potential Benefits Studied
- Significant weight loss — up to 12.8 kg (28 lbs) average in 24-week Phase II trials at 1mg; 11.3 kg at 0.5mg
- Appetite suppression — robust reduction in caloric intake via dopaminergic and serotonergic pathways
- Resting metabolic rate increase — norepinephrine reuptake inhibition contributes to elevated baseline energy expenditure
- Waist circumference reduction — significant reductions in abdominal fat markers in clinical data
- Lipid profile improvements — favorable changes in triglycerides and HDL observed in trial subjects
- Neurodegenerative research — original indication; dopaminergic activity continues to be studied in Parkinson’s and Alzheimer’s contexts
Dosage & Administration
Tesofensine 500mcg is an oral formulation taken once daily in the morning. The 500mcg (0.5mg) dose corresponds directly to the mid-range dose used in the pivotal Lancet trial, which produced 11.3 kg of average weight loss over 24 weeks. Researchers typically start at lower doses (0.25mg or less) and titrate upward based on individual response. Taking with food may help mitigate any nausea in the initial weeks. This information is presented for research reference only; tesofensine is not approved by the FDA for human use.
Where to Find It
Tesofensine 500mcg is available for research purposes at Combat Research: Tesofensine 500mcg — combatresearch.is.
Conclusion
Tesofensine occupies a unique position in weight-loss research: it is one of the few compounds with robust Phase II human clinical trial data showing efficacy far exceeding anything approved at the time of publication. The triple monoamine mechanism is well-understood, and the 2008 Lancet data remains frequently cited. For researchers studying appetite regulation, metabolic rate, and weight management, tesofensine remains a high-signal compound worth thorough investigation.
Disclaimer
This article is for educational and research purposes only. Tesofensine is not approved by the FDA for human use and is not intended to diagnose, treat, cure, or prevent any disease or condition. All clinical data referenced here comes from published research trials. Combat Research supplies this compound for laboratory and research use only. Consult a qualified healthcare professional before considering any experimental compound.
